血浆p-tau181与NfL纵向关联阿尔茨海默病神经退行性变
该纵向队列研究纳入1113名参与者,分析血浆p-tau181和神经丝轻链(NfL)与神经退行性变及认知下降的关联。结果显示血浆p-tau181变化与认知下降及AD特征脑区代谢和灰质体积减少相关,且这些关联仅限于淀粉样蛋白β阳性个体;p-tau181为AD特异性标志物,而NfL在淀粉样蛋白β阴性者中也与超出AD典型模式的神经退行性变相关。
要点
- 血浆p-tau181纵向变化与认知下降及AD特征脑区神经退行性变相关。
- 上述关联仅见于淀粉样蛋白β阳性个体,提示p-tau181的AD特异性。
- 血浆NfL在淀粉样蛋白β阴性者中亦与超出AD典型模式的神经退行性变相关。
核心结论
- 血浆p-tau181是可预测和监测神经退行性变及认知下降的便捷标志物,且与NfL不同,具有AD特异性。
研究设计与样本
- 纵向队列研究,数据来自阿尔茨海默病神经影像学倡议2007年2月1日至2016年6月6日,随访血样长达8年,血浆p-tau181于2020年测定。
- 多中心观察性研究纳入1113名参与者,包括认知未受损者和认知受损者(轻度认知障碍和AD痴呆)。
主要发现
- 血浆p-tau181纵向变化与认知下降相关(认知未受损:r=-0.24,P<.001;认知受损:r=0.34,P<.001)。
- 血浆p-tau181纵向变化与AD特征脑区葡萄糖代谢前瞻性下降相关(认知未受损:r=-0.05,P=.48;认知受损:r=-0.27,P<.001)。
- 血浆p-tau181纵向变化与AD特征脑区灰质体积前瞻性下降相关(认知未受损:r=-0.19,P<.001;认知受损:r=-0.31,P<.001)。
- 上述关联仅限于淀粉样蛋白β阳性个体。
- 中介分析发现约25%至45%的血浆p-tau181对认知测量的效应由神经影像衍生的神经退行性变标志物中介。
临床怎么用
- 血浆p-tau181可作为临床实践和治疗试验中监测AD进展的候选生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Plasma phosphorylated tau at threonine 181 (p-tau181) has been proposed as an easily accessible biomarker for the detection of Alzheimer disease (AD) pathology, but its ability to monitor disease progression in AD remains unclear. OBJECTIVE: To study the potential of longitudinal plasma p-tau181 measures for assessing neurodegeneration progression and cognitive decline in AD in comparison to plasma neurofilament light chain (NfL), a disease-nonspecific marker of neuronal injury. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal cohort study included data from the Alzheimer's Disease Neuroimaging Initiative from February 1, 2007, to June 6, 2016. Follow-up blood sampling was performed for up to 8 years. Plasma p-tau181 measurements were performed in 2020. This was a multicentric observational study of 1113 participants, including cognitively unimpaired participants as well as patients with cognitive impairment (mild cognitive impairment and AD dementia). Participants were eligible for inclusion if they had available plasma p-tau181 and NfL measurements and at least 1 fluorine-18-labeled fluorodeoxyglucose (FDG) positron emission tomography (PET) or structural magnetic resonance imaging scan performed at the same study visit. Exclusion criteria included any significant neurologic disorder other than suspected AD; presence of infection, infarction, or multiple lacunes as detected by magnetic resonance imaging; and any significant systemic condition that could lead to difficulty complying with the protocol. EXPOSURES: Plasma p-tau181 and NfL measured with single-molecule array technology. MAIN OUTCOMES AND MEASURES: Longitudinal imaging markers of neurodegeneration (FDG PET and structural magnetic resonance imaging) and cognitive test scores (Preclinical Alzheimer Cognitive Composite and Alzheimer Disease Assessment Scale-Cognitive Subscale with 13 tasks). Data were analyzed from June 20 to August 15, 2020. RESULTS: Of the 1113 participants (mean [SD] age, 74.0 [7.6] years; 600 men [53.9%]; 992 non-Hispanic White participants [89.1%]), a total of 378 individuals (34.0%) were cognitively unimpaired (CU) and 735 participants (66.0%) were cognitively impaired (CImp). Of the CImp group, 537 (73.1%) had mild cognitive impairment, and 198 (26.9%) had AD dementia. Longitudinal changes of plasma p-tau181 were associated with cognitive decline (CU: r = -0.24, P < .001; CImp: r = 0.34, P < .001) and a prospective decrease in glucose metabolism (CU: r = -0.05, P = .48; CImp: r = -0.27, P < .001) and gray matter volume (CU: r = -0.19, P < .001; CImp: r = -0.31, P < .001) in highly AD-characteristic brain regions. These associations were restricted to amyloid-β-positive individuals. Both plasma p-tau181 and NfL were independently associated with cognition and neurodegeneration in brain regions typically affected in AD. However, NfL was also associated with neurodegeneration in brain regions exceeding this AD-typical spatial pattern in amyloid-β-negative participants. Mediation analyses found that approximately 25% to 45% of plasma p-tau181 outcomes on cognition measures were mediated by the neuroimaging-derived markers of neurodegeneration, suggesting links between plasma p-tau181 and cognition independent of these measures. CONCLUSIONS AND RELEVANCE: Study findings suggest that plasma p-tau181 was an accessible and scalable marker for predicting and monitoring neurodegeneration and cognitive decline and was, unlike plasma NfL, AD specific. The study findings suggest implications for the use of plasma biomarkers as measures to monitor AD progression in clinical practice and treatment trials.
引用
- Moscoso A, Grothe MJ, Ashton NJ, et al. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurol. 2021. PMID: 33427873. doi:10.1001/jamaneurol.2020.4986
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。